Investors
Since the company’s inception, Tetraphase has developed a robust antibiotics platform that offers the potential to dramatically improve the treatment of serious bacterial infections, particularly those involving the toughest Gram-negative, multidrug-resistant bacteria.
Aligned with our mission is our commitment to our shareholders. We value their support and dedication to our company’s success. As such, our leadership takes pride in working in the most efficient and fiscally responsible manner to maximize our financial resources and ensure the highest return on investment for shareholders.
